Gary D. Friedman
Gary D. Friedman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Laurel A. Habel
Division of Research Kaiser Permanente Northern California Oakland California USA
5 shared publications Ninah Achacoso
Division of Research, Oakland, CA
3 shared publications- Arthur L. Klatsky
Senior Consultant in Cardiology and an Adjunct Investigator in the Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA.
2 shared publications - David Baer
Hematologist and Oncologist at the Oakland Medical Center in CA.
2 shared publications - H. Nicole Tran
Internist at the Oakland Medical Center in CA.
2 shared publications - Natalia Udaltsova
Data Consultant at the Division of Research in Oakland, CA.
2 shared publications
Latest Publications
- 1 March 2019
- Published by The Permanente Federation in The Permanente Journal
- Vol. 23 (1)
Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California
Epidemiologic analyses of gabapentin use and cancer risk in Kaiser Permanente Northern California were previously carried out in a collaborative study and independently evaluated in a UK database. To update these epidemiologic analyses with 7.5 more years of follow-up. Case-control analyses using conditional logistic regression to estimate relative risk by odds ratios using the prior collaboration's criteria for identifying positive drug-cancer associations and our more stringent criteria requiring stronger association, lower p values, and evidence of dose response. New associations were reanalyzed with additional control for limited measures of smoking and alcohol use. Gabapentin-cancer associations. No previously found associations met our stringent criteria, but cancers of the mouth/pharynx, esophagus, liver, and vagina did. All odds ratios for 3 or more and 8 or more prescriptions were moderately reduced by control for smoking and alcohol. Substantial elevations of risk of mouth/pharynx, liver, and vaginal cancers were associated with only 1 prescription dispensed. Sensitivity analyses aimed at possible confounding and other biases did not change our conclusions but did reveal a markedly increased risk of vaginal cancer in gabapentin users with epilepsy compared with users without. The reduced magnitude of relative risk with control for smoking and alcohol use suggests confounding by known risk factors. Biologically implausible elevated risk from just 1 prescription suggests confounding by indication. Either or both of these concerns applies to each of the 4 cancer sites associated with gabapentin use. Updated analyses show little if any evidence for carcinogenic effects of gabapentin.
- 1 March 2019
- Published by The Permanente Federation in The Permanente Journal
- Vol. 23 (1)
Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California
Epidemiologic analyses of gabapentin use and cancer risk in Kaiser Permanente Northern California were previously carried out in a collaborative study and independently evaluated in a UK database. To update these epidemiologic analyses with 7.5 more years of follow-up. Case-control analyses using conditional logistic regression to estimate relative risk by odds ratios using the prior collaboration's criteria for identifying positive drug-cancer associations and our more stringent criteria requiring stronger association, lower p values, and evidence of dose response. New associations were reanalyzed with additional control for limited measures of smoking and alcohol use. Gabapentin-cancer associations. No previously found associations met our stringent criteria, but cancers of the mouth/pharynx, esophagus, liver, and vagina did. All odds ratios for 3 or more and 8 or more prescriptions were moderately reduced by control for smoking and alcohol. Substantial elevations of risk of mouth/pharynx, liver, and vaginal cancers were associated with only 1 prescription dispensed. Sensitivity analyses aimed at possible confounding and other biases did not change our conclusions but did reveal a markedly increased risk of vaginal cancer in gabapentin users with epilepsy compared with users without. The reduced magnitude of relative risk with control for smoking and alcohol use suggests confounding by known risk factors. Biologically implausible elevated risk from just 1 prescription suggests confounding by indication. Either or both of these concerns applies to each of the 4 cancer sites associated with gabapentin use. Updated analyses show little if any evidence for carcinogenic effects of gabapentin.
- 1 June 2017
- Published by The Permanente Federation in The Permanente Journal
- Vol. 21 (2) , 16-133
Research Letter: Anticholinergic Drugs and the Gallbladder —A Neglected Effect?
Gary D Friedman, MD, MS; Ninah Achacoso, MS; Laurel A Habel, PhD Perm J 2017;21:16-133 [Full Citation] https://doi.org/10.7812/TPP/16-133 E-pub
- 1 June 2017
- Published by The Permanente Federation in The Permanente Journal
- Vol. 21 (2) , 16-133
Research Letter: Anticholinergic Drugs and the Gallbladder —A Neglected Effect?
Gary D Friedman, MD, MS; Ninah Achacoso, MS; Laurel A Habel, PhD Perm J 2017;21:16-133 [Full Citation] https://doi.org/10.7812/TPP/16-133 E-pub
- 1 June 2015
- Published by The Permanente Federation in The Permanente Journal
- Vol. 19 (2) , 28-34
Alcohol Intake, Beverage Choice, and Cancer: A Cohort Study in a Large Kaiser Permanente Population
The Permanente Journal advances knowledge in scientific research, clinical medicine, and innovative health care delivery.
- 1 June 2015
- Published by The Permanente Federation in The Permanente Journal
- Vol. 19 (2) , 28-34
Alcohol Intake, Beverage Choice, and Cancer: A Cohort Study in a Large Kaiser Permanente Population
The Permanente Journal advances knowledge in scientific research, clinical medicine, and innovative health care delivery.
- 22 April 2015
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 79 (5) , 872-873
Confounding by alcohol use: benzodiazepines and risk of liver cancer
- 22 April 2015
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 79 (5) , 872-873
Confounding by alcohol use: benzodiazepines and risk of liver cancer
- 26 November 2013
- Published by Springer Nature in Cancer Causes & Control
- Vol. 25 (2) , 251-258
Antidepressants and testicular cancer
Re-examine association of fluoxetine and paroxetine with risk of testicular cancer noted in drug screening, with 4 years more follow-up and expanded study of these and other antidepressant drugs.
- 26 November 2013
- Published by Springer Nature in Cancer Causes & Control
- Vol. 25 (2) , 251-258
Antidepressants and testicular cancer
Re-examine association of fluoxetine and paroxetine with risk of testicular cancer noted in drug screening, with 4 years more follow-up and expanded study of these and other antidepressant drugs.
- 1 June 2013
- Published by The Permanente Federation in The Permanente Journal
- Vol. 17 (2) , 23-29
Predictors of Lung Cancer: Noteworthy Cell Type Differences
H Nicole Tran, MD, PhD; Yan Li, MD, PhD; Stanton Siu, MD; David Baer MD; Gary D Friedman, MD, MS; Natalia Udaltsova, PhD; Arthur L Klatsky, MD Perm J 2013 Spring; 17(2):23-29 http://dx.doi.org/10.7812/TPP/12-104 Abstract Objective: To study risk factors for c
- 1 June 2013
- Published by The Permanente Federation in The Permanente Journal
- Vol. 17 (2) , 23-29
Predictors of Lung Cancer: Noteworthy Cell Type Differences
H Nicole Tran, MD, PhD; Yan Li, MD, PhD; Stanton Siu, MD; David Baer MD; Gary D Friedman, MD, MS; Natalia Udaltsova, PhD; Arthur L Klatsky, MD Perm J 2013 Spring; 17(2):23-29 http://dx.doi.org/10.7812/TPP/12-104 Abstract Objective: To study risk factors for c
- Open Access
- 10 September 2012
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (16) , 1246-1251
Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites
In screening pharmaceuticals for possible carcinogenic effects, an increased risk of cancer of the lip was identified in persons who received 3 or more prescriptions of the diuretic hydrochlorothiazide and the calcium channel blocker nifedipine.1 A causal relationship is biologically plausible because sun exposure is an established risk factor for lip cancer2 and hydrochlorothiazide and nifedipine are photosensitizers.3,4 For the present study, we conducted more extensive analyses of the risk of lip cancer in relation to hydrochlorothiazide, nifedipine, and the following other commonly used antihypertensive drugs: the combination of hydrochlorothiazide with triamterene, a potassium-sparing diuretic; lisinopril, an angiotensin-converting enzyme inhibitor; and atenolol, a β-adrenergic blocker. In addition to hydrochlorothiazide and nifedipine, triamterene is an established photosensitizer, and lisinopril is likely to be a photosensitizer; atenolol is not recognized as such.4,5 Associations were analyzed by the number of prescriptions received and duration of use of the drug with adjustment for cigarette smoking, a known risk factor for lip cancer.
- 10 September 2012
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (16) , 1246-1251
Open AccessAntihypertensive Drugs and Lip Cancer in Non-Hispanic Whites
In screening pharmaceuticals for possible carcinogenic effects, an increased risk of cancer of the lip was identified in persons who received 3 or more prescriptions of the diuretic hydrochlorothiazide and the calcium channel blocker nifedipine.1 A causal relationship is biologically plausible because sun exposure is an established risk factor for lip cancer2 and hydrochlorothiazide and nifedipine are photosensitizers.3,4 For the present study, we conducted more extensive analyses of the risk of lip cancer in relation to hydrochlorothiazide, nifedipine, and the following other commonly used antihypertensive drugs: the combination of hydrochlorothiazide with triamterene, a potassium-sparing diuretic; lisinopril, an angiotensin-converting enzyme inhibitor; and atenolol, a β-adrenergic blocker. In addition to hydrochlorothiazide and nifedipine, triamterene is an established photosensitizer, and lisinopril is likely to be a photosensitizer; atenolol is not recognized as such.4,5 Associations were analyzed by the number of prescriptions received and duration of use of the drug with adjustment for cigarette smoking, a known risk factor for lip cancer.